DR. MAY ABDO-MATKIWSKY D.O. NPI 1306887708

NPI Details

DR. May Abdo-matkiwsky, D.O. is a hematology and oncology internal medicine in Sparta, NJ with 26 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. May Abdo-matkiwsky, D.O. NPI is 1306887708. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: NEW YORK COLLEGE OF OSTEO MEDICINE OF NEW YORK INSTITUTE OF TECHNOLOGY
Graduation Year:2000

The provider's business location address is:

89 SPARTA AVE
SUITE 130
SPARTA, NJ
ZIP 07871-777
Phone: (973) 726-0005
Fax: (973) 726-4668

The NPI 1306887708 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, ferric derisomaltose, 10 mg (HCPCS:J1437)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Blood test, clotting time (HCPCS:85610)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Anticoagulant management of patient taking warfarin (HCPCS:93793)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Drawing of blood for a medical problem (HCPCS:99195)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Administration of influenza virus vaccine (HCPCS:G0008)

The enumeration date for this NPI number is 6/9/2006 and was last updated on 4/18/2013.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: